177 related articles for article (PubMed ID: 31436568)
1. Serum and urinary biomarkers for detection and active surveillance of prostate cancer.
Becerra MF; Bhat A; Mouzannar A; Atluri VS; Punnen S
Curr Opin Urol; 2019 Nov; 29(6):593-597. PubMed ID: 31436568
[TBL] [Abstract][Full Text] [Related]
2. Blood-based and urinary prostate cancer biomarkers: a review and comparison of novel biomarkers for detection and treatment decisions.
Hendriks RJ; van Oort IM; Schalken JA
Prostate Cancer Prostatic Dis; 2017 Mar; 20(1):12-19. PubMed ID: 27922627
[TBL] [Abstract][Full Text] [Related]
3. Novel tools to improve patient selection and monitoring on active surveillance for low-risk prostate cancer: a systematic review.
van den Bergh RC; Ahmed HU; Bangma CH; Cooperberg MR; Villers A; Parker CC
Eur Urol; 2014 Jun; 65(6):1023-31. PubMed ID: 24491309
[TBL] [Abstract][Full Text] [Related]
4. Urine TMPRSS2:ERG Plus PCA3 for Individualized Prostate Cancer Risk Assessment.
Tomlins SA; Day JR; Lonigro RJ; Hovelson DH; Siddiqui J; Kunju LP; Dunn RL; Meyer S; Hodge P; Groskopf J; Wei JT; Chinnaiyan AM
Eur Urol; 2016 Jul; 70(1):45-53. PubMed ID: 25985884
[TBL] [Abstract][Full Text] [Related]
5. Contemporary role of prostate cancer antigen 3 in the management of prostate cancer.
Auprich M; Bjartell A; Chun FK; de la Taille A; Freedland SJ; Haese A; Schalken J; Stenzl A; Tombal B; van der Poel H
Eur Urol; 2011 Nov; 60(5):1045-54. PubMed ID: 21871709
[TBL] [Abstract][Full Text] [Related]
6. [New challenges and earlier approved methods in the laboratory diagnosis of prostate cancer].
Kovács GL
Magy Onkol; 2014 Dec; 58(4):301-9. PubMed ID: 25517448
[TBL] [Abstract][Full Text] [Related]
7. Prostate Cancer Detection and Prognosis: From Prostate Specific Antigen (PSA) to Exosomal Biomarkers.
Filella X; Foj L
Int J Mol Sci; 2016 Oct; 17(11):. PubMed ID: 27792187
[TBL] [Abstract][Full Text] [Related]
8. The role of prostate cancer antigen 3 (PCA3) in prostate cancer detection.
Ploussard G; de la Taille A
Expert Rev Anticancer Ther; 2018 Oct; 18(10):1013-1020. PubMed ID: 30016891
[TBL] [Abstract][Full Text] [Related]
9. Combination of Prostate Cancer Antigen 3 and Prostate-Specific Antigen Improves Diagnostic Accuracy in Men at Risk of Prostate Cancer.
Cao L; Lee CH; Ning J; Handy BC; Wagar EA; Meng QH
Arch Pathol Lab Med; 2018 Sep; 142(9):1106-1112. PubMed ID: 29547000
[TBL] [Abstract][Full Text] [Related]
10. Liquid biomarkers in active surveillance.
Dall'Era M
World J Urol; 2022 Jan; 40(1):21-26. PubMed ID: 33590279
[TBL] [Abstract][Full Text] [Related]
11. PCA3-based nomogram for predicting prostate cancer and high grade cancer on initial transrectal guided biopsy.
Elshafei A; Chevli KK; Moussa AS; Kara O; Chueh SC; Walter P; Hatem A; Gao T; Jones JS; Duff M
Prostate; 2015 Dec; 75(16):1951-7. PubMed ID: 26384170
[TBL] [Abstract][Full Text] [Related]
12. Urinary Biomarkers for Prostate Cancer.
Tosoian JJ; Ross AE; Sokoll LJ; Partin AW; Pavlovich CP
Urol Clin North Am; 2016 Feb; 43(1):17-38. PubMed ID: 26614026
[TBL] [Abstract][Full Text] [Related]
13. Risk stratification of prostate cancer in the modern era.
Behesnilian AS; Reiter RE
Curr Opin Urol; 2015 May; 25(3):246-51. PubMed ID: 25730325
[TBL] [Abstract][Full Text] [Related]
14. Utility of PCA3 in patients undergoing repeat biopsy for prostate cancer.
Wu AK; Reese AC; Cooperberg MR; Sadetsky N; Shinohara K
Prostate Cancer Prostatic Dis; 2012 Mar; 15(1):100-5. PubMed ID: 22042252
[TBL] [Abstract][Full Text] [Related]
15. Urinary biomarkers in prostate cancer detection and monitoring progression.
Wu D; Ni J; Beretov J; Cozzi P; Willcox M; Wasinger V; Walsh B; Graham P; Li Y
Crit Rev Oncol Hematol; 2017 Oct; 118():15-26. PubMed ID: 28917266
[TBL] [Abstract][Full Text] [Related]
16. Risk Stratification by Urinary Prostate Cancer Gene 3 Testing Before Magnetic Resonance Imaging-Ultrasound Fusion-targeted Prostate Biopsy Among Men With No History of Biopsy.
Fenstermaker M; Mendhiratta N; Bjurlin MA; Meng X; Rosenkrantz AB; Huang R; Deng FM; Zhou M; Huang WC; Lepor H; Taneja SS
Urology; 2017 Jan; 99():174-179. PubMed ID: 27562202
[TBL] [Abstract][Full Text] [Related]
17. An up-to-date catalogue of urinary markers for the management of prostate cancer.
Brönimann S; Pradere B; Karakiewicz P; Huebner NA; Briganti A; Shariat SF
Curr Opin Urol; 2020 Sep; 30(5):684-688. PubMed ID: 32701725
[TBL] [Abstract][Full Text] [Related]
18. In-parallel comparative evaluation between multiparametric magnetic resonance imaging, prostate cancer antigen 3 and the prostate health index in predicting pathologically confirmed significant prostate cancer in men eligible for active surveillance.
Porpiglia F; Cantiello F; De Luca S; Manfredi M; Veltri A; Russo F; Sottile A; Damiano R
BJU Int; 2016 Oct; 118(4):527-34. PubMed ID: 26350955
[TBL] [Abstract][Full Text] [Related]
19. [The role of a single PCA3 test before a first negative prostate biopsy: 5-year follow-up].
Bernardeau S; Charles T; Fromont-Hankard G; Irani J
Prog Urol; 2017 Apr; 27(5):325-330. PubMed ID: 28385586
[TBL] [Abstract][Full Text] [Related]
20. Expression of PCA3 and PSA genes as a biomarker for differential diagnosis of nodular hyperplasia and prostate cancer.
Coelho FF; Guimarães FL; Cabral WL; Salles PG; Mateo EC; Nogueira e Nogueira LM; Fonseca CE; Gomes KB
Genet Mol Res; 2015 Oct; 14(4):13519-31. PubMed ID: 26535666
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
